文献速递肝病

脂肪性肝病新命名及代谢功能障碍相关脂肪性肝病定义的意义

Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
PubMed 文献 · Aliment Pharmacol Ther · 2024-01-01

美国与欧洲肝病学会采纳了脂肪性肝病(SLD)新命名及代谢功能障碍相关脂肪性肝病(MASLD)定义。本文通过文献检索回顾命名演变,讨论其对研究与临床实践的影响。新命名伞式分类包括MASLD、酒精相关性肝病及新实体MetALD(酒精摄入增多的MASLD);尽管定义改变,既往NAFLD患者中超过95%符合MASLD诊断标准。

要点

  • MASLD诊断需肝脂肪变及至少一项代谢危险因素,可与其他肝病共存。
  • 新命名伞式分类包括MASLD、酒精相关性肝病及新实体MetALD。
  • 既往NAFLD患者中超过95%符合MASLD诊断标准。

核心结论

  • 新命名既是挑战也是机遇,需在各类利益相关者中传播与教育,并推动SLD谱系流行病学、自然史、诊断、生物标志物和管理策略的新研究。

研究设计与样本

  • 本文为综述,通过文献检索回顾脂肪性肝病命名演变,检索关键词涉及MASLD与非酒精性脂肪性肝病(NAFLD)。

主要发现

  • SLD伞式分类将患者归入MASLD、酒精相关性肝病及新实体MetALD(酒精摄入增多的MASLD)。
  • MASLD诊断需肝脂肪变及至少一项代谢危险因素,且可与其他肝病如慢性病毒性肝炎共存。
  • 尽管定义改变,既往NAFLD患者中超过95%符合MASLD诊断标准。
  • 未来临床试验与生物标志物研究可能继续排除合并其他肝病者。

关键数值与推荐

  • MASLD诊断标准为肝脂肪变加至少一项代谢危险因素。
  • 既往NAFLD患者中超过95%符合MASLD诊断标准。

临床怎么用

  • 多数MASLD患者在初级保健和非肝病机构就诊,需与其他利益相关者沟通以确保疾病意识和顺利采纳新命名。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The American and European liver associations have endorsed new nomenclature of steatotic liver disease (SLD) and definition of metabolic dysfunction-associated steatotic liver disease (MASLD). AIMS: To review the historical development leading to the changes and to discuss the implications of the changes on research and clinical practice METHODS: We performed a literature search using keywords related to MASLD and non-alcoholic fatty liver disease (NAFLD). RESULTS: The SLD umbrella allows classification of patients under the key categories of MASLD, alcohol-associated liver disease and a new entity termed MetALD, which represents MASLD with increased alcohol intake. The diagnosis of MASLD requires the demonstration of hepatic steatosis and at least one metabolic risk factor, whereas MASLD can co-exist with other liver diseases such as chronic viral hepatitis. Despite the change in definition, over 95% of patients previously known as having NAFLD fulfil diagnostic criteria for MASLD. It is conceivable that future clinical trials and biomarker studies will continue to exclude concomitant liver diseases. As most patients with MASLD are seen at primary care and non-hepatology settings, communication with other stakeholders is essential to ensure disease awareness and smooth adoption of the changes. CONCLUSIONS: The new nomenclature is both a challenge, given the need for dissemination and education across the spectrum of stakeholders, and an opportunity to bring everyone together and spark new research to better understand epidemiology, natural history, diagnosis, biomarkers and management strategies across the spectrum of SLD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Loomba R, Wong VW. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024. PMID: 38153279. doi:10.1111/apt.17846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。